Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review
Open Access
- 29 July 2022
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 17, 3343-3359
Abstract
The recent advancements in hybrid positron emission tomography–magnetic resonance imaging systems (PET/MRI) have brought massive value in the investigation of disease processes, in the development of novel treatments, in the monitoring of both therapy response and disease progression, and, not least, in the introduction of new multidisciplinary molecular imaging approaches. While offering potential advantages over PET/CT, the hybrid PET/MRI proved to improve both the image quality and lesion detectability. In particular, it showed to be an effective tool for the study of metabolic information about lesions and pathological conditions affecting the brain, from a better tumor characterization to the analysis of metabolic brain networks. Based on the PRISMA guidelines, this work presents a systematic review on PET/MRI in basic research and clinical differential diagnosis on brain oncology and neurodegenerative disorders. The analysis includes literature works and clinical case studies, with a specific focus on the use of PET tracers and MRI contrast agents, which are usually employed to perform hybrid PET/MRI studies of brain tumors. A systematic literature search for original diagnostic studies is performed using PubMed/MEDLINE, Scopus and Web of Science. Patients, study, and imaging characteristics were extracted from the selected articles. The analysis included acquired data pooling, heterogeneity testing, sensitivity analyses, used tracers, and reported patient outcomes. Our analysis shows that, while PET/MRI for the brain is a promising diagnostic method for early diagnosis, staging and recurrence in patients with brain diseases, a better definition of the role of tracers and imaging agents in both clinical and preclinical hybrid PET/MRI applications is needed and further efforts should be devoted to the standardization of the contrast imaging protocols, also considering the emerging agents and multimodal probes.Keywords
This publication has 95 references indexed in Scilit:
- Comparison of 18F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain TumorsJournal of Nuclear Medicine, 2014
- Value of 11C-methionine PET in imaging brain tumours and metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- PET/MRI for Neurologic ApplicationsJournal of Nuclear Medicine, 2012
- Simultaneous PET/MR imaging of the brain: feasibility of cerebral blood flow measurements with FAIR-TrueFISP arterial spin labeling MRIActa Radiologica, 2012
- Simultaneous PET/MR imaging in a human brain PET/MR system in 50 patients—Current state of image qualityEuropean Journal of Radiology, 2012
- Multifunctional nanoparticles for multimodal imaging and theragnosisChemical Society Reviews, 2011
- Whole-body hybrid PET/MRI: ready for clinical use?European Journal of Nuclear Medicine and Molecular Imaging, 2011
- The potential of PET/MR for brain imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour gradingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Guest editorial: The conception of FDG-PET imagingSeminars in Nuclear Medicine, 2002